Usnic acid based thiazole-hydrazones as multi-targeting inhibitors of a wide spectrum of SARS-CoV-2 viruses

Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can c...

Full description

Saved in:
Bibliographic Details
Published inNew journal of chemistry Vol. 47; no. 43; pp. 19865 - 19879
Main Authors Yarovaya, Olga I, Filimonov, Aleksandr S, Baev, Dmitriy S, Borisevich, Sophia S, Chirkova, Varvara Yu, Zaykovskaya, Anna V, Mordvinova, Ekaterina D, Belenkaya, Svetlana V, Shcherbakov, Dmitriy N, Luzina, Olga A, Pyankov, Oleg V, Salakhutdinov, Nariman F
Format Journal Article
LanguageEnglish
Published CAMBRIDGE Royal Soc Chemistry 06.11.2023
Royal Society of Chemistry
Subjects
Online AccessGet full text
ISSN1144-0546
1369-9261
DOI10.1039/d3nj03598k

Cover

Loading…
Abstract Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (−)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 μM. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent (+)-7a with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. We have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects.
AbstractList Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (−)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 μM. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent (+)-7a with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. We have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects.
Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (−)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 μM. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent (+)-7a with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects.
Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (-)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 mu M. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent (+)-7a with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. We have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects.
Author Mordvinova, Ekaterina D
Pyankov, Oleg V
Filimonov, Aleksandr S
Chirkova, Varvara Yu
Borisevich, Sophia S
Zaykovskaya, Anna V
Belenkaya, Svetlana V
Yarovaya, Olga I
Baev, Dmitriy S
Shcherbakov, Dmitriy N
Luzina, Olga A
Salakhutdinov, Nariman F
AuthorAffiliation Leninski pr., 61
State Research Center of Virology and Biotechnology VECTOR
Rospotrebnadzor
Department of Medicinal Chemistry
Altay State University
N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS
Lavrentyev av
Laboratory of Chemical Physics
Ufa Institute of Chemistry Ufa Federal Research Center
71 Pr. Oktyabrya
AuthorAffiliation_xml – sequence: 0
  name: State Research Center of Virology and Biotechnology VECTOR
– sequence: 0
  name: Laboratory of Chemical Physics
– sequence: 0
  name: Ufa Institute of Chemistry Ufa Federal Research Center
– sequence: 0
  name: Rospotrebnadzor
– sequence: 0
  name: Leninski pr., 61
– sequence: 0
  name: Department of Medicinal Chemistry
– sequence: 0
  name: Lavrentyev av
– sequence: 0
  name: N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS
– sequence: 0
  name: 71 Pr. Oktyabrya
– sequence: 0
  name: Altay State University
Author_xml – sequence: 1
  givenname: Olga I
  surname: Yarovaya
  fullname: Yarovaya, Olga I
– sequence: 2
  givenname: Aleksandr S
  surname: Filimonov
  fullname: Filimonov, Aleksandr S
– sequence: 3
  givenname: Dmitriy S
  surname: Baev
  fullname: Baev, Dmitriy S
– sequence: 4
  givenname: Sophia S
  surname: Borisevich
  fullname: Borisevich, Sophia S
– sequence: 5
  givenname: Varvara Yu
  surname: Chirkova
  fullname: Chirkova, Varvara Yu
– sequence: 6
  givenname: Anna V
  surname: Zaykovskaya
  fullname: Zaykovskaya, Anna V
– sequence: 7
  givenname: Ekaterina D
  surname: Mordvinova
  fullname: Mordvinova, Ekaterina D
– sequence: 8
  givenname: Svetlana V
  surname: Belenkaya
  fullname: Belenkaya, Svetlana V
– sequence: 9
  givenname: Dmitriy N
  surname: Shcherbakov
  fullname: Shcherbakov, Dmitriy N
– sequence: 10
  givenname: Olga A
  surname: Luzina
  fullname: Luzina, Olga A
– sequence: 11
  givenname: Oleg V
  surname: Pyankov
  fullname: Pyankov, Oleg V
– sequence: 12
  givenname: Nariman F
  surname: Salakhutdinov
  fullname: Salakhutdinov, Nariman F
BookMark eNqNks9LHDEUx4NY8Ed78V4I9GaJTSaTbOYoY_3RSgvd2uuQTV7crLvJmmQU_euddWUL4sFc3iN8Pt8HedlD2yEGQOiA0SNGefPN8jCjXDTqZgvtMi4b0lSSbQ89q2tCRS130F7OM0oZG0m2i26ucvAGa-MtnugMFpep149xDmT6YNPQBchYZ7zo58WTotM1FB-usQ9TP_Elpoyjwxrfews4L8GU1C9WV-PjP2PSxn-kwnc-9RnyR_TB6XmGTy91H12dfv_bnpPL32cX7fElMZVihQjZUG25s-C4EbUbVc5KJQSMhGONc1S6Rk2MGoqQlDOrqaXOKlfpkZAAfB99WecuU7ztIZduFvsUhpFdpZSsasEFG6iva-oeJtFl4yEY6JbJL3R66IYHoorXXNLVWdHq_XTriy4-hjb2oQzq4Vo1KeacwG00RrvV1roT_uvH89Z-DjB9BZuXsJK0n7-tfF4rKZtN9P-PwJ8AchWkPg
CitedBy_id crossref_primary_10_3390_M1894
crossref_primary_10_1093_bib_bbae513
crossref_primary_10_1134_S1070363224010080
crossref_primary_10_3390_v16020215
Cites_doi 10.1016/j.ejmech.2018.10.055
10.1007/s12033-023-00667-5
10.1016/j.bmc.2014.10.033
10.1056/NEJMoa2118542
10.1093/nar/28.1.235
10.1007/s11101-020-09717-1
10.1016/j.molstruc.2021.130506
10.1097/JS9.0000000000000276
10.1002/jmv.28326
10.3390/v14102154
10.1177/2040206616636992
10.1039/C2MD20242E
10.1128/spectrum.00563-22
10.1126/sciadv.abg7607
10.1016/j.biopha.2021.111430
10.3390/molecules24203711
10.3390/v13020174
10.1038/s41586-022-05514-2
10.1021/acscentsci.3c00538
10.3390/biom11060787
10.1038/d41586-021-03614-z
10.1007/s12010-022-04103-3
10.1038/s41467-019-13993-7
10.1002/ptr.7151
10.1002/cmdc.202000924
10.1080/14786419.2023.2235715
10.3390/chemosensors11020135
10.1080/13543776.2018.1472239
10.1007/s11356-022-19770-2
10.1016/j.bmcl.2012.09.084
10.1126/science.abb4489
10.1126/science.abb3405
10.3390/molecules27051743
10.1038/s41598-022-16964-z
10.1021/acs.jmedchem.2c01005
10.3390/v14010119
10.3390/v14061295
10.1002/mco2.239
10.1016/j.ebiom.2021.103703
10.1016/j.molstruc.2021.130665
10.1021/acs.jnatprod.2c00015
10.1039/D1SM01181B
10.2307/1221768
10.1038/s41598-022-17506-3
10.1007/s10600-012-0258-5
10.1056/NEJMoa2001017
10.1021/acsptsci.0c00130
10.1007/s13659-021-00317-w
10.1002/jmv.27541
10.1021/acs.jctc.1c00302
10.1371/journal.pone.0042846
10.1021/acs.analchem.0c02449
10.1016/S0300-9084(02)01386-X
10.1007/s41061-022-00399-1
10.1002/mco2.151
10.1038/s41467-020-16080-4
10.1039/c2md20242e
10.1039/d1sm01181b
10.1038/s41467-022-30086-0
10.1038/s41586-020-2223-y
ContentType Journal Article
Copyright Copyright Royal Society of Chemistry 2023
Copyright_xml – notice: Copyright Royal Society of Chemistry 2023
DBID AAYXX
CITATION
17B
1KM
BLEPL
BNZSX
DTL
EGQ
7SR
8BQ
8FD
H9R
JG9
KA0
DOI 10.1039/d3nj03598k
DatabaseName CrossRef
Web of Knowledge
Index Chemicus
Web of Science Core Collection
Web of Science - Science Citation Index Expanded - 2023
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Engineered Materials Abstracts
METADEX
Technology Research Database
Illustrata: Natural Sciences
Materials Research Database
ProQuest Illustrata: Technology Collection
DatabaseTitle CrossRef
Web of Science
Materials Research Database
ProQuest Illustrata: Natural Sciences
Engineered Materials Abstracts
ProQuest Illustrata: Technology Collection
Technology Research Database
METADEX
DatabaseTitleList
CrossRef
Materials Research Database
Web of Science
Database_xml – sequence: 1
  dbid: 1KM
  name: Index Chemicus
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1369-9261
EndPage 19879
ExternalDocumentID 001083436000001
10_1039_D3NJ03598K
d3nj03598k
GrantInformation_xml – fundername: Synthesis of compounds, testing against a main viral protease and as inhibitors of virus entry, performing molecular modeling was supported by the Russian Science Foundation grant No 22-23-00618. Section of the study "Biological testing for an infectious v
GroupedDBID ---
-DZ
-JG
-~X
0-7
0R~
123
29N
4.4
705
70~
7~J
AAEMU
AAIWI
AAJAE
AAMEH
AANOJ
AAWGC
AAXHV
AAXPP
ABASK
ABCQX
ABDVN
ABEMK
ABJNI
ABPDG
ABRYZ
ABXOH
ACGFS
ACIWK
ACLDK
ACNCT
ADMRA
ADSRN
AEFDR
AENEX
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFRDS
AFVBQ
AGEGJ
AGKEF
AGRSR
AGSTE
AHGCF
ALMA_UNASSIGNED_HOLDINGS
ANUXI
APEMP
ASKNT
AUDPV
AZFZN
BLAPV
BSQNT
C6K
CS3
D0L
DU5
EBS
ECGLT
EE0
EF-
F5P
GGIMP
GNO
H13
HZ~
H~N
IDZ
J3I
L7B
M4U
N9A
O9-
OK1
P2P
R7B
R7C
R7D
RAOCF
RCNCU
RNS
RPMJG
RRA
RRC
RSCEA
SKA
SKF
SKH
SLH
TN5
TWZ
VH6
YNT
YQT
AAYXX
AFRZK
AKMSF
ALUYA
CITATION
R56
17B
1KM
BLEPL
DTL
GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED
GROUPED_WOS_WEB_OF_SCIENCE
7SR
8BQ
8FD
H9R
JG9
KA0
ID FETCH-LOGICAL-c281t-5690ad3fdef3c54f72fd6855e75f19ff06f98bc86f956031da0d0fd8f2a756ee3
ISICitedReferencesCount 5
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=001083436000001
ISSN 1144-0546
IngestDate Mon Jun 30 08:27:28 EDT 2025
Fri May 30 07:49:16 EDT 2025
Fri Aug 29 15:50:35 EDT 2025
Tue Jul 01 02:51:41 EDT 2025
Thu Apr 24 22:57:07 EDT 2025
Tue Dec 17 20:58:29 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 43
Keywords DRUG
DERIVATIVES
Language English
LinkModel OpenURL
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-c281t-5690ad3fdef3c54f72fd6855e75f19ff06f98bc86f956031da0d0fd8f2a756ee3
Notes https://doi.org/10.1039/d3nj03598k
Electronic supplementary information (ESI) available. See DOI
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ORCID 0000-0002-0492-154X
0000-0002-2333-4893
0000-0003-2798-2844
0000-0001-8481-0470
PQID 2886245351
PQPubID 2048886
PageCount 15
ParticipantIDs webofscience_primary_001083436000001CitationCount
rsc_primary_d3nj03598k
webofscience_primary_001083436000001
crossref_primary_10_1039_D3NJ03598K
crossref_citationtrail_10_1039_D3NJ03598K
proquest_journals_2886245351
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-06
PublicationDateYYYYMMDD 2023-11-06
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-06
  day: 06
PublicationDecade 2020
PublicationPlace CAMBRIDGE
PublicationPlace_xml – name: CAMBRIDGE
– name: Cambridge
PublicationTitle New journal of chemistry
PublicationTitleAbbrev NEW J CHEM
PublicationYear 2023
Publisher Royal Soc Chemistry
Royal Society of Chemistry
Publisher_xml – name: Royal Soc Chemistry
– name: Royal Society of Chemistry
References 7
Yang (D3NJ03598K/cit53/1) 2020; 92
Cowan (D3NJ03598K/cit1/1) 1983; 32
Lee (D3NJ03598K/cit33/1) 2022; 13
Hu (D3NJ03598K/cit36/1) 2022
Berman (D3NJ03598K/cit57/1) 2000; 28
Chernyshov (D3NJ03598K/cit28/1) 2022; 380
Iketani (D3NJ03598K/cit10/1) 2023; 613
La Monica (D3NJ03598K/cit34/1) 2022; 65
Rosa (D3NJ03598K/cit47/1) 2023
Sokolov (D3NJ03598K/cit4/1) 2012; 22
Mordvinova (D3NJ03598K/cit50/1) 2023; 11
Zhu (D3NJ03598K/cit8/1) 2020; 382
Filimonov (D3NJ03598K/cit24/1) 2022; 14
Jin (D3NJ03598K/cit32/1) 2020
Domingo (D3NJ03598K/cit38/1) 2021; 74
Yang (D3NJ03598K/cit35/1) 2021; 16
Lee (D3NJ03598K/cit37/1) 2020; 11
Thakur (D3NJ03598K/cit42/1) 2022; 94
Ong (D3NJ03598K/cit43/1) 2023; 95
Luzina (D3NJ03598K/cit55/1) 2012; 48
Channabasappa (D3NJ03598K/cit45/1) 2023; 109
Lockbaum (D3NJ03598K/cit56/1) 2021; 13
Merarchi (D3NJ03598K/cit13/1) 2021; 35
Ma (D3NJ03598K/cit29/1) 2020; 3
Bowers (D3NJ03598K/cit59/1) 2006
Ebob (D3NJ03598K/cit15/1) 2021; 11
Zakharenko (D3NJ03598K/cit25/1) 2019; 161
(D3NJ03598K/cit54/1) 2006
Callaway (D3NJ03598K/cit41/1) 2021; 600
Hammond (D3NJ03598K/cit9/1) 2022; 386
Campanella (D3NJ03598K/cit3/1) 2002; 84
Obakachi (D3NJ03598K/cit27/1) 2021; 1241
Dai (D3NJ03598K/cit31/1) 2020; 368
Hu (D3NJ03598K/cit40/1) 2022; 18
Shtro (D3NJ03598K/cit6/1) 2014; 22
Ao (D3NJ03598K/cit46/1) 2023; 4
Liskova (D3NJ03598K/cit16/1) 2021; 138
Prateeksha (D3NJ03598K/cit21/1) 2021; 1240
Macedo (D3NJ03598K/cit2/1) 2021; 20
Gupta (D3NJ03598K/cit20/1) 2022; 194
Filimonov (D3NJ03598K/cit26/1) 2019; 24
Yarovaya (D3NJ03598K/cit48/1) 2022; 14
Luzina (D3NJ03598K/cit7/1) 2018; 28
Caserta (D3NJ03598K/cit39/1) 2022; 10
Oh (D3NJ03598K/cit19/1) 2022; 12
Zhang (D3NJ03598K/cit30/1) 2020; 368
Shtro (D3NJ03598K/cit5/1) 2015; 24
Jalencas (D3NJ03598K/cit12/1) 2013; 4
Chhetri (D3NJ03598K/cit18/1) 2022; 85
Coban (D3NJ03598K/cit22/1) 2021; 11
Roney (D3NJ03598K/cit23/1)
Suenaga (D3NJ03598K/cit60/1) 2012; 7
Rosa (D3NJ03598K/cit51/1) 2021; 7
Touret (D3NJ03598K/cit52/1) 2022; 12
González-Maldonado (D3NJ03598K/cit17/1) 2022; 27
Borisevich (D3NJ03598K/cit49/1) 2022; 14
Parums (D3NJ03598K/cit44/1) 2023; 29
Al-Harrasi (D3NJ03598K/cit14/1) 2022; 29
Hu (D3NJ03598K/cit11/1) 2023; 9
Lu (D3NJ03598K/cit58/1) 2021; 17
Macedo, DCS (WOS:000568262400001) 2021; 20
Cowan, R. S. (001083436000001.1) 1983; 32
Zakharenko, AL (WOS:000451498200040) 2019; 161
Merarchi, M (WOS:000661861200001) 2021; 35
Filimonov, AS (WOS:000496249500080) 2019; 24
Liskova, A (WOS:000641386500004) 2021; 138
Yang, Y (WOS:000563047900010) 2020; 92
Luzina, OA (WOS:000306833200009) 2012; 48
Jin, ZM (WOS:000537932300001) 2020; 582
Rosa, L (WOS:001028774700001) 2024; 38
Zhang, LL (WOS:000528513300041) 2020; 368
Thakur, V (WOS:000736131800001) 2022; 94
(001083436000001.54) 2006
Hu, YM (WOS:001035682300001) 2023
Obakachi, VA (WOS:000670212600006) 2021; 1241
Yarovaya, OI (WOS:000816661400001) 2022; 14
Mordvinova, ED (WOS:000938929200001) 2023; 11
Sokolov, DN (WOS:000310583100013) 2012; 22
Lee, JB (WOS:000790385800009) 2022; 13
Jalencas, X (WOS:000312547200011) 2013; 4
Shtro, A. A. (BCI:BCI201600792100) 2015; 24
Borisevich, SS (WOS:000749830700001) 2022; 14
Ao, DY (WOS:000949578700001) 2023; 4
Channabasappa, NK (WOS:000999427500050) 2023; 109
Lee, JY (WOS:000537248100001) 2020; 11
Domingo, P (WOS:000744272700007) 2021; 74
Callaway, E (WOS:000727856300008) 2021; 600
Gupta, A (WOS:000835626900002) 2022; 194
Ma, CL (WOS:000599606200018) 2020; 3
Chhetri, BK (WOS:000778916900022) 2022; 85
Al-Harrasi, A (WOS:000777207600005) 2022; 29
Lockbaum, GJ (WOS:000623306100001) 2021; 13
Filimonov, AS (WOS:000873640300001) 2022; 14
Hu, YW (WOS:000831276100001) 2022; 18
Luzina, OA (WOS:000433950900006) 2018; 28
Hammond, J (WOS:000755954300001) 2022; 386
Campanella, L (WOS:000177111800009) 2002; 84
Ebob, OT (WOS:000695375300001) 2021; 11
Zhu, N (WOS:000517119800008) 2020; 382
Roney, M (WOS:000929264800001) 2024; 66
Touret, F (WOS:000830058200001) 2022; 12
Oh, E (WOS:000834790800022) 2022; 12
Suenaga, A (WOS:000307733800031) 2012; 7
Rosa, A (WOS:000655906900036) 2021; 7
Chernyshov, VV (WOS:000839670500003) 2022; 380
La Monica, G (WOS:000863534600001) 2022; 65
Berman, HM (WOS:000084896300069) 2000; 28
Parums, D. V. (001083436000001.44) 2023; 29
Iketani, S (WOS:000901944300001) 2023; 613
Caserta, L. C. (001083436000001.39) 2022; 10
Hu, Q (WOS:000825282200001) 2022; 3
Dai, WH (WOS:000544017600040) 2020; 368
Yang, KS (WOS:000596948600001) 2021; 16
Lu, C (WOS:000674289800037) 2021; 17
Ong, CP (WOS:000891847500001) 2023; 95
Coban, MA (WOS:000665434600001) 2021; 11
González-Maldonado, P (WOS:000768165400001) 2022; 27
Prateeksha, G (WOS:000664244700007) 2021; 1240
Shtro, AA (WOS:000345650800011) 2014; 22
Bowers, K. J. (001083436000001.59) 2006
References_xml – issn: 2006
  year: 7
  end-page: 1
– issn: 2006
  end-page: 43
  publication-title: IEEE
  doi: Bowers Chow Xu Dror Eastwood Gregersen Klepeis Kolossvary Moraes Sacerdoti Salmon Shan Shaw
– volume: 161
  start-page: 581
  year: 2019
  ident: D3NJ03598K/cit25/1
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.10.055
– ident: D3NJ03598K/cit23/1
  publication-title: Mol. Biotechnol.
  doi: 10.1007/s12033-023-00667-5
– volume: 22
  start-page: 6826
  year: 2014
  ident: D3NJ03598K/cit6/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2014.10.033
– volume: 386
  start-page: 1397
  year: 2022
  ident: D3NJ03598K/cit9/1
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2118542
– volume: 28
  start-page: 235
  year: 2000
  ident: D3NJ03598K/cit57/1
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/28.1.235
– volume: 20
  start-page: 609
  year: 2021
  ident: D3NJ03598K/cit2/1
  publication-title: Phytochem. Rev.
  doi: 10.1007/s11101-020-09717-1
– volume: 1240
  start-page: 130506
  year: 2021
  ident: D3NJ03598K/cit21/1
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2021.130506
– volume: 109
  start-page: 1054
  year: 2023
  ident: D3NJ03598K/cit45/1
  publication-title: Int. J. Surg.
  doi: 10.1097/JS9.0000000000000276
– start-page: 43
  volume-title: IEEE
  year: 2006
  ident: D3NJ03598K/cit59/1
– volume: 95
  start-page: e28326
  year: 2023
  ident: D3NJ03598K/cit43/1
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.28326
– volume: 14
  start-page: 2154
  year: 2022
  ident: D3NJ03598K/cit24/1
  publication-title: Viruses
  doi: 10.3390/v14102154
– volume: 24
  start-page: 92
  year: 2015
  ident: D3NJ03598K/cit5/1
  publication-title: Antiviral Chem. Chemother.
  doi: 10.1177/2040206616636992
– volume: 4
  start-page: 80
  year: 2013
  ident: D3NJ03598K/cit12/1
  publication-title: MedChemComm
  doi: 10.1039/C2MD20242E
– volume: 10
  start-page: 1
  year: 2022
  ident: D3NJ03598K/cit39/1
  publication-title: Microbiol. Spectr.
  doi: 10.1128/spectrum.00563-22
– volume: 7
  start-page: eabg7607
  year: 2021
  ident: D3NJ03598K/cit51/1
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abg7607
– volume: 138
  start-page: 111430
  year: 2021
  ident: D3NJ03598K/cit16/1
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2021.111430
– volume: 24
  start-page: 3711
  year: 2019
  ident: D3NJ03598K/cit26/1
  publication-title: Molecules
  doi: 10.3390/molecules24203711
– volume: 13
  start-page: 174
  year: 2021
  ident: D3NJ03598K/cit56/1
  publication-title: Viruses
  doi: 10.3390/v13020174
– volume: 613
  start-page: 558
  year: 2023
  ident: D3NJ03598K/cit10/1
  publication-title: Nature
  doi: 10.1038/s41586-022-05514-2
– volume: 9
  start-page: 1658
  year: 2023
  ident: D3NJ03598K/cit11/1
  publication-title: ACS Cent. Sci.
  doi: 10.1021/acscentsci.3c00538
– volume: 11
  start-page: 787
  year: 2021
  ident: D3NJ03598K/cit22/1
  publication-title: Biomolecules
  doi: 10.3390/biom11060787
– volume: 600
  start-page: 197
  year: 2021
  ident: D3NJ03598K/cit41/1
  publication-title: Nature
  doi: 10.1038/d41586-021-03614-z
– volume: 194
  start-page: 6386
  year: 2022
  ident: D3NJ03598K/cit20/1
  publication-title: Appl. Biochem. Biotechnol.
  doi: 10.1007/s12010-022-04103-3
– volume: 11
  start-page: 1
  year: 2020
  ident: D3NJ03598K/cit37/1
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-13993-7
– volume: 35
  start-page: 5384
  year: 2021
  ident: D3NJ03598K/cit13/1
  publication-title: Phyther. Res.
  doi: 10.1002/ptr.7151
– volume: 16
  start-page: 942
  year: 2021
  ident: D3NJ03598K/cit35/1
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.202000924
– start-page: 1
  year: 2023
  ident: D3NJ03598K/cit47/1
  publication-title: Nat. Prod. Res.
  doi: 10.1080/14786419.2023.2235715
– volume: 11
  start-page: 135
  year: 2023
  ident: D3NJ03598K/cit50/1
  publication-title: Chemosensors
  doi: 10.3390/chemosensors11020135
– volume: 28
  start-page: 477
  year: 2018
  ident: D3NJ03598K/cit7/1
  publication-title: Expert Opin. Ther. Pat.
  doi: 10.1080/13543776.2018.1472239
– volume: 13
  start-page: 1
  year: 2022
  ident: D3NJ03598K/cit33/1
  publication-title: Nat. Commun.
– volume: 29
  start-page: 42404
  year: 2022
  ident: D3NJ03598K/cit14/1
  publication-title: Environ. Sci. Pollut. Res.
  doi: 10.1007/s11356-022-19770-2
– volume: 22
  start-page: 7060
  year: 2012
  ident: D3NJ03598K/cit4/1
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2012.09.084
– volume: 368
  start-page: 1331
  year: 2020
  ident: D3NJ03598K/cit31/1
  publication-title: Science
  doi: 10.1126/science.abb4489
– volume: 368
  start-page: 409
  year: 2020
  ident: D3NJ03598K/cit30/1
  publication-title: Science
  doi: 10.1126/science.abb3405
– volume: 27
  start-page: 1743
  year: 2022
  ident: D3NJ03598K/cit17/1
  publication-title: Molecules
  doi: 10.3390/molecules27051743
– volume: 12
  start-page: 12609
  year: 2022
  ident: D3NJ03598K/cit52/1
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-022-16964-z
– volume: 65
  start-page: 12500
  year: 2022
  ident: D3NJ03598K/cit34/1
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.2c01005
– volume: 14
  start-page: 119
  year: 2022
  ident: D3NJ03598K/cit49/1
  publication-title: Viruses
  doi: 10.3390/v14010119
– volume: 14
  start-page: 1295
  year: 2022
  ident: D3NJ03598K/cit48/1
  publication-title: Viruses
  doi: 10.3390/v14061295
– volume: 4
  start-page: e239
  year: 2023
  ident: D3NJ03598K/cit46/1
  publication-title: MedComm
  doi: 10.1002/mco2.239
– volume: 74
  start-page: 103703
  year: 2021
  ident: D3NJ03598K/cit38/1
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2021.103703
– volume: 1241
  start-page: 130665
  year: 2021
  ident: D3NJ03598K/cit27/1
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2021.130665
– volume: 85
  start-page: 657
  year: 2022
  ident: D3NJ03598K/cit18/1
  publication-title: J. Nat. Prod.
  doi: 10.1021/acs.jnatprod.2c00015
– volume: 18
  start-page: 5833
  year: 2022
  ident: D3NJ03598K/cit40/1
  publication-title: Soft Matter
  doi: 10.1039/D1SM01181B
– volume: 32
  start-page: 698
  year: 1983
  ident: D3NJ03598K/cit1/1
  publication-title: Taxon
  doi: 10.2307/1221768
– volume: 12
  start-page: 13118
  year: 2022
  ident: D3NJ03598K/cit19/1
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-022-17506-3
– start-page: 1
  year: 2020
  ident: D3NJ03598K/cit32/1
  publication-title: Nature
– volume: 48
  start-page: 385
  year: 2012
  ident: D3NJ03598K/cit55/1
  publication-title: Chem. Nat. Compd.
  doi: 10.1007/s10600-012-0258-5
– volume: 382
  start-page: 727
  year: 2020
  ident: D3NJ03598K/cit8/1
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2001017
– volume: 29
  start-page: 10
  year: 2023
  ident: D3NJ03598K/cit44/1
  publication-title: Med. Sci. Monit.
– volume: 3
  start-page: 1265
  year: 2020
  ident: D3NJ03598K/cit29/1
  publication-title: ACS Pharmacol. Transl. Sci.
  doi: 10.1021/acsptsci.0c00130
– volume: 11
  start-page: 611
  year: 2021
  ident: D3NJ03598K/cit15/1
  publication-title: Nat. Prod. Bioprospect.
  doi: 10.1007/s13659-021-00317-w
– volume: 94
  start-page: 1821
  year: 2022
  ident: D3NJ03598K/cit42/1
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.27541
– volume: 17
  start-page: 4291
  year: 2021
  ident: D3NJ03598K/cit58/1
  publication-title: J. Chem. Theory Comput.
  doi: 10.1021/acs.jctc.1c00302
– start-page: 3
  year: 2022
  ident: D3NJ03598K/cit36/1
  publication-title: MedComm
– volume: 7
  start-page: e42846
  year: 2012
  ident: D3NJ03598K/cit60/1
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0042846
– volume: 92
  start-page: 10930
  year: 2020
  ident: D3NJ03598K/cit53/1
  publication-title: Anal. Chem.
  doi: 10.1021/acs.analchem.0c02449
– start-page: 1
  year: 2006
  ident: D3NJ03598K/cit54/1
– volume: 84
  start-page: 329
  year: 2002
  ident: D3NJ03598K/cit3/1
  publication-title: Biochimie
  doi: 10.1016/S0300-9084(02)01386-X
– volume: 380
  start-page: 42
  year: 2022
  ident: D3NJ03598K/cit28/1
  publication-title: Top. Curr. Chem.
  doi: 10.1007/s41061-022-00399-1
– volume: 600
  start-page: 197
  year: 2021
  ident: WOS:000727856300008
  article-title: HOW BAD IS OMICRON? WHAT SCIENTISTS KNOW SO FAR
  publication-title: NATURE
  doi: 10.1038/d41586-021-03614-z
– volume: 27
  start-page: ARTN 1743
  year: 2022
  ident: WOS:000768165400001
  article-title: Screening of Natural Products Inhibitors of SARS-CoV-2 Entry
  publication-title: MOLECULES
  doi: 10.3390/molecules27051743
– volume: 94
  start-page: 1821
  year: 2022
  ident: WOS:000736131800001
  article-title: OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear
  publication-title: JOURNAL OF MEDICAL VIROLOGY
  doi: 10.1002/jmv.27541
– volume: 3
  start-page: ARTN e151
  year: 2022
  ident: WOS:000825282200001
  article-title: The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19
  publication-title: MEDCOMM
  doi: 10.1002/mco2.151
– volume: 1241
  start-page: ARTN 130665
  year: 2021
  ident: WOS:000670212600006
  article-title: Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells
  publication-title: JOURNAL OF MOLECULAR STRUCTURE
  doi: 10.1016/j.molstruc.2021.130665
– volume: 17
  start-page: 4291
  year: 2021
  ident: WOS:000674289800037
  article-title: OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space
  publication-title: JOURNAL OF CHEMICAL THEORY AND COMPUTATION
  doi: 10.1021/acs.jctc.1c00302
– volume: 35
  start-page: 5384
  year: 2021
  ident: WOS:000661861200001
  article-title: Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs
  publication-title: PHYTOTHERAPY RESEARCH
  doi: 10.1002/ptr.7151
– volume: 29
  start-page: 10
  year: 2023
  ident: 001083436000001.44
  publication-title: Med. Sci. Monit
– volume: 3
  start-page: 1265
  year: 2020
  ident: WOS:000599606200018
  article-title: Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors
  publication-title: ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
  doi: 10.1021/acsptsci.0c00130
– volume: 194
  start-page: 6386
  year: 2022
  ident: WOS:000835626900002
  article-title: Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses
  publication-title: APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
  doi: 10.1007/s12010-022-04103-3
– volume: 161
  start-page: 581
  year: 2019
  ident: WOS:000451498200040
  article-title: Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topotecan on in vivo tumor models
  publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1016/j.ejmech.2018.10.055
– volume: 386
  start-page: 1397
  year: 2022
  ident: WOS:000755954300001
  article-title: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
  publication-title: NEW ENGLAND JOURNAL OF MEDICINE
  doi: 10.1056/NEJMoa2118542
– volume: 24
  start-page: 92
  year: 2015
  ident: BCI:BCI201600792100
  article-title: Derivatives of usnic acid inhibit broad range of influenza viruses and protect mice from lethal influenza infection
  publication-title: Antiviral Chemistry & Chemotherapy
  doi: 10.1177/2040206616636992
– volume: 11
  start-page: ARTN 2358
  year: 2020
  ident: WOS:000537248100001
  article-title: N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer's disease
  publication-title: NATURE COMMUNICATIONS
  doi: 10.1038/s41467-020-16080-4
– volume: 12
  start-page: ARTN 12609
  year: 2022
  ident: WOS:000830058200001
  article-title: In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
  publication-title: SCIENTIFIC REPORTS
  doi: 10.1038/s41598-022-16964-z
– volume: 48
  start-page: 385
  year: 2012
  ident: WOS:000306833200009
  article-title: Synthesis of aurones based on usninic acid
  publication-title: CHEMISTRY OF NATURAL COMPOUNDS
  doi: 10.1007/s10600-012-0258-5
– volume: 28
  start-page: 477
  year: 2018
  ident: WOS:000433950900006
  article-title: Usnic acid and its derivatives for pharmaceutical use: a patent review (2000-2017)
  publication-title: EXPERT OPINION ON THERAPEUTIC PATENTS
  doi: 10.1080/13543776.2018.1472239
– volume: 32
  year: 1983
  ident: 001083436000001.1
  publication-title: Taxon
– volume: 22
  start-page: 6826
  year: 2014
  ident: WOS:000345650800011
  article-title: Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A virus
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY
  doi: 10.1016/j.bmc.2014.10.033
– volume: 14
  start-page: ARTN 1295
  year: 2022
  ident: WOS:000816661400001
  article-title: Borneol Ester Derivatives as Entry Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses
  publication-title: VIRUSES-BASEL
  doi: 10.3390/v14061295
– year: 2006
  ident: 001083436000001.54
  publication-title: RU
– volume: 368
  start-page: 409
  year: 2020
  ident: WOS:000528513300041
  article-title: Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
  publication-title: SCIENCE
  doi: 10.1126/science.abb3405
– volume: 66
  start-page: 696
  year: 2024
  ident: WOS:000929264800001
  article-title: Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches
  publication-title: MOLECULAR BIOTECHNOLOGY
  doi: 10.1007/s12033-023-00667-5
– volume: 11
  start-page: ARTN 787
  year: 2021
  ident: WOS:000665434600001
  article-title: Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement
  publication-title: BIOMOLECULES
  doi: 10.3390/biom11060787
– volume: 28
  start-page: 235
  year: 2000
  ident: WOS:000084896300069
  article-title: The Protein Data Bank
  publication-title: NUCLEIC ACIDS RESEARCH
– volume: 10
  start-page: 1
  year: 2022
  ident: 001083436000001.39
  publication-title: Microbiol. Spectr
– volume: 7
  start-page: ARTN eabg7607
  year: 2021
  ident: WOS:000655906900036
  article-title: SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
  publication-title: SCIENCE ADVANCES
  doi: 10.1126/sciadv.abg7607
– volume: 382
  start-page: 727
  year: 2020
  ident: WOS:000517119800008
  article-title: A Novel Coronavirus from Patients with Pneumonia in China, 2019
  publication-title: NEW ENGLAND JOURNAL OF MEDICINE
  doi: 10.1056/NEJMoa2001017
– volume: 74
  start-page: ARTN 103703
  year: 2021
  ident: WOS:000744272700007
  article-title: Alpha variant SARS-CoV-2 infection: How it all starts
  publication-title: EBIOMEDICINE
  doi: 10.1016/j.ebiom.2021.103703
– volume: 24
  start-page: ARTN 3711
  year: 2019
  ident: WOS:000496249500080
  article-title: New Hydrazinothiazole Derivatives of Usnic Acid as Potent Tdp1 Inhibitors
  publication-title: MOLECULES
  doi: 10.3390/molecules24203711
– volume: 368
  start-page: 1331
  year: 2020
  ident: WOS:000544017600040
  article-title: Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
  publication-title: SCIENCE
  doi: 10.1126/science.abb4489
– volume: 12
  start-page: ARTN 13118
  year: 2022
  ident: WOS:000834790800022
  article-title: (+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay
  publication-title: SCIENTIFIC REPORTS
  doi: 10.1038/s41598-022-17506-3
– volume: 4
  start-page: ARTN e239
  year: 2023
  ident: WOS:000949578700001
  article-title: The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
  publication-title: MEDCOMM
  doi: 10.1002/mco2.239
– volume: 4
  start-page: 80
  year: 2013
  ident: WOS:000312547200011
  article-title: On the origins of drug polypharmacology
  publication-title: MEDCHEMCOMM
  doi: 10.1039/c2md20242e
– volume: 18
  start-page: 5833
  year: 2022
  ident: WOS:000831276100001
  article-title: Nanomechanical analysis of SARS-CoV-2 variants and predictions of infectiousness and lethality
  publication-title: SOFT MATTER
  doi: 10.1039/d1sm01181b
– volume: 65
  start-page: 12500
  year: 2022
  ident: WOS:000863534600001
  article-title: Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.2c01005
– year: 2006
  ident: 001083436000001.59
  publication-title: IEEE
– volume: 13
  start-page: ARTN 174
  year: 2021
  ident: WOS:000623306100001
  article-title: Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
  publication-title: VIRUSES-BASEL
  doi: 10.3390/v13020174
– volume: 380
  start-page: ARTN 42
  year: 2022
  ident: WOS:000839670500003
  article-title: Nitrogen-Containing Heterocyclic Compounds Obtained from Monoterpenes or Their Derivatives: Synthesis and Properties
  publication-title: TOPICS IN CURRENT CHEMISTRY
  doi: 10.1007/s41061-022-00399-1
– volume: 85
  start-page: 657
  year: 2022
  ident: WOS:000778916900022
  article-title: Marine Natural Products as Leads against SARS-CoV-2 Infection
  publication-title: JOURNAL OF NATURAL PRODUCTS
  doi: 10.1021/acs.jnatprod.2c00015
– volume: 11
  start-page: 611
  year: 2021
  ident: WOS:000695375300001
  article-title: Natural Products as Potential Lead Compounds for Drug Discovery Against SARS-CoV-2
  publication-title: NATURAL PRODUCTS AND BIOPROSPECTING
  doi: 10.1007/s13659-021-00317-w
– volume: 109
  start-page: 1054
  year: 2023
  ident: WOS:000999427500050
  article-title: SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects
  publication-title: INTERNATIONAL JOURNAL OF SURGERY
  doi: 10.1097/JS9.0000000000000276
– volume: 14
  start-page: ARTN 119
  year: 2022
  ident: WOS:000749830700001
  article-title: Simulation of Molecular Dynamics of SARS-CoV-2 S-Protein in the Presence of Multiple Arbidol Molecules: Interactions and Binding Mode Insights
  publication-title: VIRUSES-BASEL
  doi: 10.3390/v14010119
– volume: 29
  start-page: 42404
  year: 2022
  ident: WOS:000777207600005
  article-title: Targeting natural products against SARS-CoV-2
  publication-title: ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
  doi: 10.1007/s11356-022-19770-2
– volume: 11
  start-page: ARTN 135
  year: 2023
  ident: WOS:000938929200001
  article-title: Inhibitors of the RBD-ACE-2 Found among a Wide Range of Dyes by the Immunoassay Method
  publication-title: CHEMOSENSORS
  doi: 10.3390/chemosensors11020135
– volume: 13
  start-page: ARTN 2421
  year: 2022
  ident: WOS:000790385800009
  article-title: Rapid access to polycyclic N-heteroarenes from unactivated, simple azines via a base-promoted Minisci-type annulation
  publication-title: NATURE COMMUNICATIONS
  doi: 10.1038/s41467-022-30086-0
– volume: 92
  start-page: 10930
  year: 2020
  ident: WOS:000563047900010
  article-title: The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor
  publication-title: ANALYTICAL CHEMISTRY
  doi: 10.1021/acs.analchem.0c02449
– volume: 95
  year: 2023
  ident: WOS:000891847500001
  article-title: Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants
  publication-title: JOURNAL OF MEDICAL VIROLOGY
  doi: 10.1002/jmv.28326
– volume: 22
  start-page: 7060
  year: 2012
  ident: WOS:000310583100013
  article-title: Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
  doi: 10.1016/j.bmcl.2012.09.084
– volume: 613
  start-page: 558
  year: 2023
  ident: WOS:000901944300001
  article-title: Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
  publication-title: NATURE
  doi: 10.1038/s41586-022-05514-2
– volume: 20
  start-page: 609
  year: 2021
  ident: WOS:000568262400001
  article-title: Usnic acid: from an ancient lichen derivative to promising biological and nanotechnology applications
  publication-title: PHYTOCHEMISTRY REVIEWS
  doi: 10.1007/s11101-020-09717-1
– volume: 1240
  start-page: ARTN 130506
  year: 2021
  ident: WOS:000664244700007
  article-title: Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches
  publication-title: JOURNAL OF MOLECULAR STRUCTURE
  doi: 10.1016/j.molstruc.2021.130506
– volume: 14
  start-page: ARTN 2154
  year: 2022
  ident: WOS:000873640300001
  article-title: (+)-Usnic Acid and Its Derivatives as Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses
  publication-title: VIRUSES-BASEL
  doi: 10.3390/v14102154
– volume: 16
  start-page: 942
  year: 2021
  ident: WOS:000596948600001
  article-title: A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors**
  publication-title: CHEMMEDCHEM
  doi: 10.1002/cmdc.202000924
– volume: 582
  start-page: 289
  year: 2020
  ident: WOS:000537932300001
  article-title: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
  publication-title: NATURE
  doi: 10.1038/s41586-020-2223-y
– volume: 84
  start-page: 329
  year: 2002
  ident: WOS:000177111800009
  article-title: Molecular characterization and action of usnic acid: a drug that inhibits proliferation of mouse polyomavirus in vitro and whose main target is RNA transcription
  publication-title: BIOCHIMIE
– volume: 138
  start-page: ARTN 111430
  year: 2021
  ident: WOS:000641386500004
  article-title: Flavonoids against the SARS-CoV-2 induced inflammatory storm
  publication-title: BIOMEDICINE & PHARMACOTHERAPY
  doi: 10.1016/j.biopha.2021.111430
– volume: 38
  start-page: 2129
  year: 2024
  ident: WOS:001028774700001
  article-title: Neutralizing activity of Usnic acid and α-cyclodextrins complex against SARS-CoV-2 spike pseudovirus
  publication-title: NATURAL PRODUCT RESEARCH
  doi: 10.1080/14786419.2023.2235715
– year: 2023
  ident: WOS:001035682300001
  article-title: Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
  publication-title: ACS CENTRAL SCIENCE
  doi: 10.1021/acscentsci.3c00538
– volume: 7
  start-page: ARTN e42846
  year: 2012
  ident: WOS:000307733800031
  article-title: An Efficient Computational Method for Calculating Ligand Binding Affinities
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0042846
SSID ssj0011761
Score 2.4296606
Snippet Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus...
Source Web of Science
SourceID proquest
webofscience
crossref
rsc
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 19865
SubjectTerms Binding sites
Chemical synthesis
Chemistry
Chemistry, Multidisciplinary
Glycoproteins
Hydrazones
Modelling
Physical Sciences
Protease
Proteins
Science & Technology
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Viruses
Title Usnic acid based thiazole-hydrazones as multi-targeting inhibitors of a wide spectrum of SARS-CoV-2 viruses
URI http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=001083436000001
https://www.proquest.com/docview/2886245351
Volume 47
WOS 001083436000001
WOSCitedRecordID wos001083436000001
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa67gFeELeJwkCW2AuqMhI718fSDW0DhkQ7tLfK9YVl7ZopaYu6n8Sv5NhxkjL6UHhJI1-iuOeLz7F9zncQOiAkiZLY444fUKWPGbmTEAl3KojAwoiFNDwFX87Dkwv_7DK4bLV-rXktLebjQ363Ma7kf6QKZSBXHSX7D5KtHwoFcA_yhStIGK5byfii0OlrGE_BigRtpF0hU3aXTaVztRI53ME8phPJGK9Bp3T6LmNYrtJxavLsmPDIn6mQXRNzmS9uTBhL79vA6WffHdJdpvmisI6G1w3V0xrjBK9yxtUzCMuzJVsZs_Tr9Afrnh7WMEmnAI5ZtrTBNZOCzUTeHdQNPjBp6o5u0nmertZrMpiPQI2XuasG2S2Mtaq22xaEmvi9cG2mhZWcA_ai5cEuy2iYAFRKdvZqei4JOS0Mfbo22XpJXOaZsJpb758kG9WCSzWr6hE9PzOMhZ8a5Vcd-N_TibWnojmjp8mo6buDdgksSUgb7faOh6ef6zMrLyrZeauBVWS4NHnf9P7T_GnWNDt5wTfaPsbOGT5Gj-wCBfdKtD1BLTl7ih70Kxk_QxODOqxRhw3q8AbUYVbge6jDDepwpjDDGnW4Qp0ualCHLeqeo4uPx8P-iWNTdjicxN7cCcLEZYIqIRXlga8iokQYB4GMAuUlSrmhSuIxj-En0PnNBXOFq0SsCIuCUEq6h9ozeM0XCPthyKUnmR-Oud6EiH3hSV-5ksKzZUI66F31T4645bPXaVWmo79l1kFv67a3JYvLxlb7lUBG9isqRiTWIVQBDbwO2gMh1f0FnV2bfpMOOliXW91C77fE1KehWYlDf2-bZn07Fs1JMX-51Yu_Qg-bT2wftUFs8jXYyvPxGwvS37y6vbw
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Usnic+acid+based+thiazole-hydrazones+as+multi-targeting+inhibitors+of+a+wide+spectrum+of+SARS-CoV-2+viruses&rft.jtitle=New+journal+of+chemistry&rft.au=Yarovaya%2C+Olga+I.&rft.au=Filimonov%2C+Aleksandr+S.&rft.au=Baev%2C+Dmitriy+S.&rft.au=Borisevich%2C+Sophia+S.&rft.date=2023-11-06&rft.issn=1144-0546&rft.eissn=1369-9261&rft.volume=47&rft.issue=43&rft.spage=19865&rft.epage=19879&rft_id=info:doi/10.1039%2FD3NJ03598K&rft.externalDBID=n%2Fa&rft.externalDocID=10_1039_D3NJ03598K
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1144-0546&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1144-0546&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1144-0546&client=summon